Figure 4

The intracellular levels of p24 antigen of VSV-G, HXB2 and BaL enveloped HIV-1 pseudotypes accumulate in early time points in lactacystin-treated BeWo cells. Intracellular p24 antigen levels for VSV-G (A), HXB2 (B), BaL (C) and envelope deficient (D) pseudotypes normalised against p24 antigen level at time point 0 (100%). BeWo cells were treated for 2 hours with 50 μM lactacystin prior to viral exposure, which greatly reduces proteasomal activity (as determined by the diminished release of the fluorogenic substrate Suc-LLVY-AMC; data not shown) without affecting cell viability (as determined by Wst-1 cell viability assays; data not shown). Bars indicate the mean of at least three independent experiments; error bars indicate SEM.